New study suggests higher buprenorphine doses could help save lives

Individuals with opioid use disorder who were prescribed a lower buprenorphine dose were 20% more likely to discontinue treatment than those on a higher dose, according to a study of patients prescribed buprenorphine in Rhode Island from 2016 to 2020, as fentanyl became widely available.

FSD Pharma Inc. (NASDAQ: HUGE) Enters Market Offering Agreement | Psychedelic Invest

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has entered into

February 21, 2024

Gilead and Arcus Biosciences expand oncology partnership deal

Share this article The investment from Gilead in Arcus is aimed at expediting the growth of co-development programmes for cancer indications. Credit: Kateryna Kon /

January 30, 2024

AstraZeneca-Daiichi Sankyo’s gastric cancer therapy approved

AstraZeneca and Daiichi Sankyo’s Enhertu achieved a confirmed ORR of 28.8% and a median PFS of 5.7 months. Credit: Robert Way/Shutterstock. AstraZeneca and Daiichi Sankyo‘s

August 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.